Impact of bariatric surgery on oral anticancer drugs: an analysis of real-world data.

Cedric Lau Ma Ida Mohmaed Ali Lishi LinDorieke E M van BalenBart A W JacobsBastiaan NuijenRobert M SmeenkNeeltje Steeghs Alwin D R Huitema

Published in: Cancer chemotherapy and pharmacology (2024)

The proposed flowchart can support optimizing the treatment with orally administered anticancer drugs in patients who underwent bariatric surgery. We recommend performing TDM in drugs that belong to BCS classes II, III, or IV. If more risk factors are present in BCS classes II or IV, a priori switches to other drugs may be advised. In specific cases, higher dosages can be provided from the start (e.g., tamoxifen).

Keyphrases

bariatric surgery
risk factors
end stage renal disease
weight loss
obese patients
ejection fraction
newly diagnosed
chronic kidney disease
drug induced
peritoneal dialysis
machine learning
electronic health record
patient reported outcomes
artificial intelligence